Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer.
Animals
Cell Line, Tumor
Disease Models, Animal
Epithelial-Mesenchymal Transition
/ genetics
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Male
Mice
Mice, Transgenic
MicroRNAs
/ agonists
Neoplasm Metastasis
/ genetics
Nuclear Proteins
/ genetics
Prostate
/ pathology
Prostatic Neoplasms, Castration-Resistant
/ genetics
Protein Methyltransferases
/ genetics
RNA, Long Noncoding
/ genetics
RNA-Seq
Xenograft Model Antitumor Assays
tRNA Methyltransferases
/ genetics
NOP2
lncRNA LINC00963
metastasis
miR-542-3p
prostate cancer
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
17 06 2020
17 06 2020
Historique:
received:
16
12
2019
accepted:
30
03
2020
pubmed:
20
6
2020
medline:
10
3
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Metastatic disease caused by castration-resistant prostate cancer (CRPC) is the principal cause of prostate cancer (PCa)-related mortality. CRPC occurs within 2-3 years of initiation of androgen deprivation therapy (ADT), which is an important factor of influencing PCa metastasis. Recent studies have revealed that non-coding RNAs in PCa can enhance metastasis and progression, while the mechanisms are still unclear. In this study, we reported that the long noncoding RNA-LINC00963 was increased in CRPC tissues and promoted migration of PCa cells in vitro and their metastasis in vivo. High levels of LINC00963 significantly decreased tumor suppressor miR-542-3p, whose levels in metastasis tissues were low compared to those in non-metastasis tissues. LINC00963 promotes and miR-542-3p inhibits metastasis. Furthermore, the expression levels of LINC00963 and miR-542-3p were positively and negatively associated with the expression of NOP2. We demonstrated that NOP2 promoted PCa by activating the epithelial-mesenchymal transition (EMT) pathway. For specific mechanism, dual luciferase reporter assays showed that miR-542-3p directly binds to both 3'-untranslated region (UTR) of LINC00963 and NOP2 mRNA. Taken together, our results show that LINC00963 acts as an inducer of PCa metastasis by binding miR-542-3p, thereby promoting NOP2. This axis may have diagnostic and therapeutic potential for advanced PCa.
Identifiants
pubmed: 32554858
pii: 103236
doi: 10.18632/aging.103236
pmc: PMC7343457
doi:
Substances chimiques
MIRN542 microRNA, human
0
MIRN542 microRNA, mouse
0
MicroRNAs
0
Nuclear Proteins
0
RNA, Long Noncoding
0
long non-coding RNA LINC00963, human
0
NOP2 protein, human
EC 2.1.1.-
Nop2 protein, mouse
EC 2.1.1.-
Protein Methyltransferases
EC 2.1.1.-
tRNA Methyltransferases
EC 2.1.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11500-11516Références
Nat Genet. 2019 Jan;51(1):138-150
pubmed: 30531872
Onco Targets Ther. 2019 Sep 02;12:7095-7109
pubmed: 31564894
Cell Cycle. 2019 May;18(9):923-931
pubmed: 30892130
Nat Rev Urol. 2019 Apr;16(4):206-207
pubmed: 30808987
Biomed Pharmacother. 2019 Feb;110:850-856
pubmed: 30557834
Oncogene. 2020 Jan;39(5):953-974
pubmed: 31601996
Am J Cancer Res. 2019 Jul 01;9(7):1367-1381
pubmed: 31392075
Cell Cycle. 2019 Oct;18(19):2454-2464
pubmed: 31411527
Am J Cancer Res. 2015 Sep 15;5(10):3198-209
pubmed: 26693070
Nucleic Acids Res. 2019 May 7;47(8):4211-4225
pubmed: 30773595
Nucleic Acids Res. 2020 Jan 8;48(D1):D118-D126
pubmed: 31713618
Onco Targets Ther. 2019 Nov 06;12:9277-9290
pubmed: 31819474
Cancer Metastasis Rev. 2014 Sep;33(2-3):377-97
pubmed: 24452759
Mol Cell. 2015 Aug 20;59(4):698-711
pubmed: 26236012
Cancer Res. 2019 Jun 15;79(12):3028-3030
pubmed: 31201165
Mol Cancer. 2019 Oct 25;18(1):147
pubmed: 31651347
Am J Cancer Res. 2017 Jan 01;7(1):159-172
pubmed: 28123857
J Med Chem. 2019 Nov 14;62(21):9541-9559
pubmed: 31593466
Exp Eye Res. 2017 May;158:73-84
pubmed: 27131906
Mol Cancer. 2019 Jun 20;18(1):109
pubmed: 31221168
N Engl J Med. 2019 Oct 10;381(15):1494-1495
pubmed: 31597033
Nat Methods. 2016 Dec 29;14(1):5-6
pubmed: 28032625
Aging (Albany NY). 2019 Dec 31;12(1):80-105
pubmed: 31895687
Mol Oncol. 2019 May;13(5):1121-1136
pubmed: 30776192
Mol Ther. 2017 Aug 2;25(8):1959-1973
pubmed: 28487115
Mol Cancer Ther. 2019 Dec;18(12):2469-2479
pubmed: 31387890
Front Oncol. 2019 Oct 04;9:912
pubmed: 31637209
J Exp Clin Cancer Res. 2017 Nov 15;36(1):159
pubmed: 29141691
Aging (Albany NY). 2019 Nov 24;11(22):10644-10663
pubmed: 31761786
Aging (Albany NY). 2020 Feb 24;12(4):3574-3593
pubmed: 32091407
J Clin Oncol. 2020 Feb 20;38(6):593-601
pubmed: 31829912
Cancer Lett. 2018 Apr 28;420:97-108
pubmed: 29409974
Eur Urol. 2020 Mar;77(3):393
pubmed: 31727449
Cancer Cell Int. 2019 Dec 3;19:323
pubmed: 31827397
Hepatology. 2014 Oct;60(4):1278-90
pubmed: 25043274